Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New research has helped to revolutionize the drug class and deliver next-generation designs and approaches.
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how were they discovered? Learn about the history of ADCs, their functions, the ADCs currently approved...
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference, including investigational KRAS degraders, approaches to drug p53 and MYC, and new AI tools for...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next generation of cancer treatments. We spoke with Andrea Wang-Gillam, MD, PhD, of Jacobio Pharmaceuticals; Kiyean...
With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the treatment of blood cancers in recent years. Here, we provide an overview of how this...
In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution, sex differences in immune responses, the discovery of a new subset of cells that promote...
Cancer immunology expert and former AACR president Elizabeth Jaffee, MD, FAACR, discusses the latest progress in the research on pancreatic cancer vaccines and explains why cancer interception in individuals at high risk is the...
Exposure to wildfire smoke may increase the risk of developing several cancers, according to research presented at the AACR Annual Meeting 2026 by Shuguang Leng, MBBS, PhD, and Qizhen Wu, PhD, both of the...
At the AACR Special Conference on Advances in Malignant Lymphoma, Ronald Levy, MD, FAACR, of Stanford University, discussed how monoclonal antibodies transformed lymphoma treatment; Michel C. Nussenzweig, MD, PhD, of The Rockefeller University, explored...
The June edition of Editors’ Picks from the AACR journals included studies on targeting neural cross-talk to stop glioblastoma recurrence, identifying patients with multiple myeloma who may benefit from debulking chemotherapy, examining considerable improvements...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More